Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer : a study protocol of a randomised phase II trial (PRIME-RT)

Hanna, C R, O’Cathail, S M, Graham, J S, Saunders, M, Samuel, L, Harrison, M, Devlin, L, Edwards, J, Gaya, D R, Kelly, C A, Lewsley, L-A, Maka, N, Morrison, P, Dinnett, L, Dillon, S, Gourlay, J, Platt, J J, Thomson, F, Adams, R A & Roxburgh, C S D 2021, 'Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer : a study protocol of a randomised phase II trial (PRIME-RT)', Radiation Oncology, vol. 16, no. 1, 163. https://doi.org/10.1186/s13014-021-01888-1